Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ELVNBullishIndustry Newsnews

High materiality8/10

Enliven to present ELVN-001 Phase 1 data at SOHO 2026, potential catalyst.

Aug 31, 2026, 6:10 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Upcoming SOHO data readouts often act as near-term catalysts for clinical-stage biotechs. Positive safety/effectiveness signals can lift valuation while negative results risk a sharp reversal; historical peers show 10-20% moves around conference data, depending on data clarity and prior credibility.

AI summary

What happened, with direct paths to the underlying reporting

Enliven will share ENABLE Phase 1 data on ELVN-001 at the SOHO 2026 meeting, with an oral presentation and a poster. The data focus on safety, tolerability, and activity against BCR-ABL1, including the T315I mutation in CP-CML patients. A favorable read could sharpen the program's valuation and accelerate near-term investor interest.

ELVN-001 ENABLE Phase 1 data to be presented at SOHO 2026. Encore from EHA 2026.
Poster and oral sessions on CP-CML, incl. T315I. Oral on Sept 10, poster Sept 9.
ENABLE Phase 1: safety/tolerability and dose-escalation data.
ELVN-001 targets BCR-ABL1, including T315I mutation; potential best-in-class.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Enliven to present ELVN-001 Phase 1 data at SOHO 2026, potential catalyst.

William Blair Initiates Coverage on ELVN, Sees ELVN-001 as CML Disruptor

Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars